{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:09:02Z","timestamp":1761588542601,"version":"build-2065373602"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100018920","name":"Ruijin Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073182"],"award-info":[{"award-number":["82073182"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008233","name":"School of Medicine, Shanghai Jiao Tong University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008233","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.intimp.2023.110881","type":"journal-article","created":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T23:33:46Z","timestamp":1693697626000},"page":"110881","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"PA","title":["Acute toxicities of intravenous, intraperitoneal, or intratumoral injection of natural killer cells in human pancreatic adenocarcinoma-bearing mice: Randomized study"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4225-9200","authenticated-orcid":false,"given":"Lei","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaojie","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mancang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.110881_b0005","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.intimp.2023.110881_b0010","doi-asserted-by":"crossref","first-page":"e554","DOI":"10.1097\/SLA.0000000000003558","article-title":"Significance of Examined Lymph Node Number in Accurate Staging and Long-term Survival in Resected Stage I-II Pancreatic Cancer-More is Better? A Large International Population-based Cohort Study","volume":"274","author":"Huang","year":"2021","journal-title":"Ann. Surg."},{"key":"10.1016\/j.intimp.2023.110881_b0015","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1136\/gutjnl-2017-314828","article-title":"Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations","volume":"68","author":"Huang","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.intimp.2023.110881_b0020","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12916-018-1120-9","article-title":"Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study","volume":"16","author":"Huang","year":"2018","journal-title":"BMC Med."},{"key":"10.1016\/j.intimp.2023.110881_b0025","article-title":"S-1 Maintenance Therapy After First-Line Treatment With Nab-Paclitaxel Plus S-1 for Advanced Pancreatic Adenocarcinoma: A Real-World Study","volume":"12","author":"Shi","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.intimp.2023.110881_b0030","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1002\/ijc.31628","article-title":"Nonsurgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003\u20132014: a large international population-based study","volume":"143","author":"Huang","year":"2018","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.intimp.2023.110881_b0035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12916-019-1304-y","article-title":"Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study","volume":"17","author":"Huang","year":"2019","journal-title":"BMC Med."},{"key":"10.1016\/j.intimp.2023.110881_b0040","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1158\/2326-6066.CIR-18-0317","article-title":"An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model","volume":"7","author":"Lee","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.intimp.2023.110881_b0045","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.jconrel.2020.07.016","article-title":"Rationally designed redirection of natural killer cells anchoring a cytotoxic ligand for pancreatic cancer treatment","volume":"326","author":"Lee","year":"2020","journal-title":"J. Control. Release"},{"key":"10.1016\/j.intimp.2023.110881_b0050","first-page":"1757","article-title":"Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a Kras(LSL-G12D) p53(LSL-R172H) Pdx1-Cre mouse model","volume":"9","author":"Hu","year":"2019","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110881_b0055","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.pharmthera.2018.04.003","article-title":"Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review","volume":"189","author":"Van Audenaerde","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.intimp.2023.110881_b0060","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.surg.2019.05.047","article-title":"Engraftment of mesothelin chimeric antigen receptor using a hybrid Sleeping Beauty\/minicircle vector into NK-92MI cells for treatment of pancreatic cancer","volume":"166","author":"Batchu","year":"2019","journal-title":"Surgery"},{"key":"10.1016\/j.intimp.2023.110881_b0065","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1053\/j.gastro.2021.12.281","article-title":"Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer","volume":"162","author":"Teng","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.intimp.2023.110881_b0070","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12010063","article-title":"Probiotic-Treated Super-Charged NK Cells Efficiently Clear Poorly Differentiated Pancreatic Tumors in Hu-BLT Mice","volume":"12","author":"Kaur","year":"2019","journal-title":"Cancers"},{"key":"10.1016\/j.intimp.2023.110881_b0075","first-page":"1643","article-title":"Efficacy of irreversible electroporation ablation combined with natural killer cells in treating locally advanced pancreatic cancer","volume":"25","author":"Pan","year":"2020","journal-title":"J. B.U.ON.: Off. J. Balkan Union Oncol."},{"key":"10.1016\/j.intimp.2023.110881_b0080","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1007\/s00432-017-2513-4","article-title":"Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III\/IV) pancreatic cancer: a promising treatment","volume":"143","author":"Lin","year":"2017","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.110881_b0085","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.imlet.2017.03.018","article-title":"Short-term clinical efficacy of percutaneous irreversible electroporation combined with allogeneic natural killer cell for treating metastatic pancreatic cancer","volume":"186","author":"Lin","year":"2017","journal-title":"Immunol. Lett."},{"key":"10.1016\/j.intimp.2023.110881_b0090","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.21873\/anticanres.13796","article-title":"Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of (125)I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma","volume":"39","author":"Xia","year":"2019","journal-title":"Anticancer Res."},{"key":"10.1016\/j.intimp.2023.110881_b0095","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fimmu.2013.00061","article-title":"NK cell isolation from liver biopsies: phenotypic and functional analysis of low cell numbers by flow cytometry","volume":"4","author":"Li","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.intimp.2023.110881_b0100","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00262-021-03005-3","article-title":"Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma","volume":"71","author":"Ohira","year":"2022","journal-title":"Cancer Immunol., Immunotherapy : CII"},{"key":"10.1016\/j.intimp.2023.110881_b0105","doi-asserted-by":"crossref","first-page":"e0225998","DOI":"10.1371\/journal.pone.0225998","article-title":"Safety and immune cell kinetics after donor natural killer cell infusion following haploidentical stem cell transplantation in children with recurrent neuroblastoma","volume":"14","author":"Choi","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.intimp.2023.110881_b0110","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Rubnitz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2023.110881_b0115","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/toxsci\/kfz098","article-title":"Current Concepts in Natural Killer Cell Biology and Application to Drug Safety Assessments","volume":"170","author":"Goyos","year":"2019","journal-title":"Toxicol. Sci.: Off. J. Soc. Toxicol."},{"key":"10.1016\/j.intimp.2023.110881_b0120","doi-asserted-by":"crossref","first-page":"753","DOI":"10.2217\/imt.09.47","article-title":"Safety analysis of ex vivo-expanded NK and NK-like T cells administered to cancer patients: a phase I clinical study","volume":"1","author":"Barkholt","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2023.110881_b0125","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/JLB.5A1019-501RR","article-title":"Safety analysis of ex vivo-expanded canine natural killer cells in a xenogeneic mouse model of graft-versus-host disease","volume":"111","author":"Kim","year":"2022","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.intimp.2023.110881_b0130","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.ccell.2020.03.018","article-title":"Cord Blood CAR-NK Cells: Favorable Initial Efficacy and Toxicity but Durability of Clinical Responses Not Yet Clear","volume":"37","author":"Karadimitris","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.intimp.2023.110881_b0135","first-page":"1083","article-title":"First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia","volume":"8","author":"Tang","year":"2018","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.intimp.2023.110881_b0140","doi-asserted-by":"crossref","first-page":"281","DOI":"10.2217\/imt-2016-0137","article-title":"Possible damage to immune-privileged sites in natural killer cell therapy in cancer patients: side effects of natural killer cell therapy","volume":"9","author":"Bolourian","year":"2017","journal-title":"Immunotherapy"},{"key":"10.1016\/j.intimp.2023.110881_b0145","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1172\/JCI132712","article-title":"Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients","volume":"130","author":"Lin","year":"2020","journal-title":"J. Clin. Invest."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923012067?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576923012067?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:05:09Z","timestamp":1761588309000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576923012067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":29,"alternative-id":["S1567576923012067"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110881","relation":{},"ISSN":["1567-5769"],"issn-type":[{"type":"print","value":"1567-5769"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Acute toxicities of intravenous, intraperitoneal, or intratumoral injection of natural killer cells in human pancreatic adenocarcinoma-bearing mice: Randomized study","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.110881","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110881"}}